Literature DB >> 9099152

Verification of parental history of coronary artery disease and associations with adult offspring risk factors in a community sample: the Bogalusa Heart Study.

K J Greenlund1, R Valdez, W Bao, W A Wattigney, S R Srinivasan, G S Berenson.   

Abstract

Positive parental history of coronary artery disease (CAD) (myocardial infarction, angina, angioplasty, bypass surgery) reported by 371 of 1,930 black and white adults aged 18 to 31 years in 1988 to 1991 in the Bogalusa Heart Study was verified by interviewing parents or next-of-kin. Error rates in reporting information concerning parental CAD and risk factors in offspring with a positive and negative parental history of CAD were examined. The 371 subjects who reported a positive parental history represented 304 families. Parental CAD could not be verified in 43 (14.1%) instances, and false-positive reports occurred in 45 (14.8%) cases. Among 216 families with confirmed CAD histories, the father had CAD in 175 (81.0%) cases and the mother in 70 (32.4%) cases. Both parents had CAD in 29 (13.4%) families. Of the parents with CAD, 46% of the fathers and 25% of the mothers died. The mean age at clinical onset of CAD was 51 years. Offspring with a confirmed positive parental history (n = 271) had significantly higher (P < 0.05) adjusted serum total and low-density lipoprotein cholesterol, plasma insulin and glucose, body mass index, and triceps and subscapular skinfolds than subjects with a negative parental history (n = 1,253). Those with an unconfirmed positive parental history (n = 51) had higher mean plasma insulin and serum high-density lipoprotein levels than those with a negative parental history; low-density lipoprotein levels were similar. Family history of CAD remains a useful indicator for screening adults at risk of developing CAD. An unverified family history may underestimate the importance of particular risk factors in epidemiologic studies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9099152     DOI: 10.1097/00000441-199704000-00005

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  7 in total

1.  Is family history of premature cardiovascular diseases appropriate for detection of dyslipidemic children in population-based preventive medicine programs? CASPIAN study.

Authors:  Roya Kelishadi; Gelayol Ardalan; Riaz Gheiratmand; Arash Ramezani
Journal:  Pediatr Cardiol       Date:  2006-11-16       Impact factor: 1.655

2.  Familial predisposition and susceptibility to the effect of other risk factors for myocardial infarction.

Authors:  M Hippe; J Vestbo; H O Hein; K Borch-Johnsen; G Jensen; T I Sørensen
Journal:  J Epidemiol Community Health       Date:  1999-05       Impact factor: 3.710

3.  Cross-sectional analysis of cardiovascular risk factors in children with parental history of premature ischemic heart disease.

Authors:  Gal Neuman; Itai Shavit; Doron Aronson; Avraham Lorber; Diana Gaitini; Roy Onn; Naim Shehadeh
Journal:  Pediatr Cardiol       Date:  2011-02-27       Impact factor: 1.655

4.  Family history and oral health: findings from the Dunedin Study.

Authors:  Dara M Shearer; W Murray Thomson; Avshalom Caspi; Terrie E Moffitt; Jonathan M Broadbent; Richie Poulton
Journal:  Community Dent Oral Epidemiol       Date:  2011-10-24       Impact factor: 3.383

Review 5.  Intergenerational continuity in oral health: a review.

Authors:  Dara M Shearer; W Murray Thomson
Journal:  Community Dent Oral Epidemiol       Date:  2010-12       Impact factor: 3.383

6.  Inter-generational continuity in periodontal health: findings from the Dunedin family history study.

Authors:  Dara M Shearer; W Murray Thomson; Avshalom Caspi; Terrie E Moffitt; Jonathan M Broadbent; Richie Poulton
Journal:  J Clin Periodontol       Date:  2011-01-31       Impact factor: 8.728

7.  Can the cardiovascular family history reported by our patients be trusted? The Norwegian Stroke in the Young Study.

Authors:  H Øygarden; A Fromm; K M Sand; G E Eide; L Thomassen; H Naess; U Waje-Andreassen
Journal:  Eur J Neurol       Date:  2015-08-21       Impact factor: 6.089

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.